Cash and cash equivalents of $132.2 million at September 30, 2024 compared to $151.0 million at September 30, 2023. As of fiscal year end, the Company anticipates at the current cash utilization rate, a runway of approximately 4 years.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVXL:
- Anavex receives EMA filing acceptance for treatment of Alzheimer’s disease
- Options Volatility and Implied Earnings Moves Today, December 23, 2024
- Options Volatility and Implied Earnings Moves This Week, December 23 – December 26, 2024
- Biotech Alert: Searches spiking for these stocks today
- Anavex announces upcoming presentation of data from ATTENTION-AD study